Neurofilament Light Chain Levels as an Early Predictive Biomarker of Neurotoxicity After CAR T-Cell Therapy

Investigators studied all consecutive adult patients who received commercial CAR T cells for relapsed/refractory B cell lymphomas at Saint-Louis Hospital between January 2019 and February 2023. Patients with pre-existing or current neurological disease were excluded.